Newsroom | 46298 results

SAN CARLOS, Califórnia--(BUSINESS WIRE)--A BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), empresa de oncologia global, anunciou hoje os resultados financeiros e as atualizações corporativas do segundo trimestre de 2025. "Nosso sólido desempenho no segundo trimestre reforça nossa trajetória como uma potência global em oncologia e destaca nossa habilidade comprovada de proporcionar crescimento sustentável e a longo prazo", afirmou John V. Oyler, cofundador, presidente e CEO da BeOn...

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 27,480 shares of the Company’s common stock to seven new employees (the “Inducement Grants”) on August 6, 2025 (the “Grant Date”). The Induc...

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Exicure, Inc. Reports Second Quarter 2025 Financial Results...

DUBLIN--(BUSINESS WIRE)--The "Navigating ICH GCP (Good Clinical Practice) E6 (R3): What You Need to Know Training Course" training has been added to ResearchAndMarkets.com's offering. This one-day training course is designed to provide clinical research professionals with a comprehensive understanding of the updated guidelines, ensuring compliance and enhancing the quality of clinical trials. The ICH GCP E6 (R3) guideline represents a significant evolution in the conduct of clinical trials, emp...

DUBLIN--(BUSINESS WIRE)--The "North America Autoimmune Disease Diagnostics Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033" has been added to ResearchAndMarkets.com's offering. The North America Autoimmune Disease Diagnostics Market accounted for USD 1.96 billion in 2024 and is expected to grow to USD 3.5 billion by 2033 at a CAGR of 6.66% during the forecast period 2025-2033. The growth is attributed to an increase in autoimmune disease cases, awareness, the develo...

DUBLIN--(BUSINESS WIRE)--The "North America Clinical Trials Market Size and Forecast Report 2025-2033" report has been added to ResearchAndMarkets.com's offering. The North America Clinical Trials Market is expected to reach US$ 33.91 billion by 2033 from US$ 20.07 billion in 2024, with a CAGR of 6.00% from 2025 to 2033. This is explained by longer clinical trial cycles, the demand for new treatments, and an increase in viral disorders as COVID-19 and diabetes, as well as advantageous governmen...

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the second quarter ended June 30, 2025, and provided recent corporate updates. “We continue to execute on our strategy, which is grounded in scientific rigor and focused on fulfilling our mission to develop next-generation prec...

SAN DIEGO--(BUSINESS WIRE)--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today reported its financial results for the three and six months ended June 30, 2025. Corporate Highlights Completed dosing of patients in PRIME Phase 1b Clinical Study of Gemini in CKD Patients Received gross proceeds of $4 million from public offering in May 2025 "The Revelation team con...

カリフォルニア州サンカルロス--(BUSINESS WIRE)--（ビジネスワイヤ） -- グローバルなオンコロジー企業であるBeOne Medicines Ltd.（NASDAQ：ONC、HKEX：06160、SSE：688235）は、2025年第2・四半期の財務結果および企業最新情報を発表しました。 「第2・四半期の力強い業績は、グローバルなオンコロジー分野のリーダーとしての当社の軌道をさらに確かなものにし、持続的かつ長期的な成長を実現する確かな能力を裏付けるものとなっています」と、BeOneの共同創業者兼会長兼最高経営責任者（CEO）であるジョン・V・オイラーは述べました。「私たちは明確な目的を持って取り組み、世界中のより多くの患者さんに革新的な医薬品を届けるという使命を前進させています。当社の血液がん領域の中核を担う製品であるBRUKINSAは承認された適応数が最も多く、クラス最高のBTK阻害剤として引き続き標準を打ち立てており、5つの適応における優れた有効性、良好な安全性、そして肯定的な患者転帰によって、米国市場でリーダーの地位を確立しています。この勢いを背景に、当社の第3...

SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), una compañía global de oncología, anunció hoy los resultados financieros y novedades corporativas del segundo trimestre de 2025. “El sólido desempeño en el segundo trimestre refuerza nuestra trayectoria como potencia mundial en oncología y subraya nuestra capacidad demostrada para lograr un crecimiento sostenible a largo plazo”, afirmó John V. Oyler, cofundador, presidente y CEO de BeOne. Estamos...